The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.
Anne M. Traynor
Research Funding - Novartis
Glen E. Leverson
No relevant relationships to disclose
Diane F Elson
No relevant relationships to disclose
Hilary R Hernan
No relevant relationships to disclose
Martha M. Larson
No relevant relationships to disclose
Jules Harris Blank
No relevant relationships to disclose
Gilbert G Fareau
No relevant relationships to disclose
Kari Braun Wisinski
No relevant relationships to disclose
Ryan J. Mattison
No relevant relationships to disclose
Herbert Chen
No relevant relationships to disclose
Rebecca S Sippel
No relevant relationships to disclose